Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Qiwei Wu

Showing results (51-60 of 55) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 55 results.
Clinical Interventions in Aging|January 14, 2025
Exploring Self-Management Behavior Profiles in Patients with Multimorbidity: A Sequential, Explanatory Mixed-Methods StudyYujia Fu, Jingjie Wu, Zhiting Guo, et al.
Health Psychology Review|July 23, 2025
The effectiveness of nudge-based interventions on self-monitoring behaviours among patients with cardiometabolic diseases: a systematic review and meta-analysisJianing Yu, Yujia Fu, Haoyang Du, et al.
The New England Journal of Medicine|June 27, 2023
Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 TrialAnia M Jastreboff, Lee M Kaplan, Juan P Frías, et al.
Nature Medicine|June 10, 2024
Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trialArun J Sanyal, Lee M Kaplan, Juan P Frias, et al.
Lancet (London, England)|November 23, 2025
Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trialDeborah B Horn, Donna H Ryan, Sanja Giljanovic Kis, et al.
Pageof 6

Showing results (51-60 of 55) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 55 results.
Clinical Interventions in Aging|January 14, 2025
Exploring Self-Management Behavior Profiles in Patients with Multimorbidity: A Sequential, Explanatory Mixed-Methods StudyYujia Fu, Jingjie Wu, Zhiting Guo, et al.
Health Psychology Review|July 23, 2025
The effectiveness of nudge-based interventions on self-monitoring behaviours among patients with cardiometabolic diseases: a systematic review and meta-analysisJianing Yu, Yujia Fu, Haoyang Du, et al.
The New England Journal of Medicine|June 27, 2023
Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 TrialAnia M Jastreboff, Lee M Kaplan, Juan P Frías, et al.
Nature Medicine|June 10, 2024
Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trialArun J Sanyal, Lee M Kaplan, Juan P Frias, et al.
Lancet (London, England)|November 23, 2025
Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trialDeborah B Horn, Donna H Ryan, Sanja Giljanovic Kis, et al.
Pageof 6